Blue Lake and CyanVac Present Promising Intranasal Vaccine Data at ISV Annual Congress

Key Insights

• Blue Lake Biotechnology and CyanVac presented positive interim Phase 1/2a data for BLB201, an intranasal vaccine candidate against respiratory syncytial virus (RSV), in RSV-seropositive children.
• Phase 1 data for CVXGA, the companies’ intranasal vaccine candidate against COVID-19, demonstrated systemic and mucosal antibody responses and T cell-mediated responses.
• Preclinical data on a PIV5-based vaccine for Lyme disease, a collaboration with Immuno Technologies, showed protection against multi-strain _Borrelia burgdorferi_ in mice.

Blue Lake Biotechnology and its affiliate CyanVac LLC announced the presentation of clinical and preclinical data on their intranasal vaccine candidates at the 2024 ISV Annual Congress in Seoul, South Korea.

The data included interim results from a Phase 1/2a pediatric study of BLB201, Blue Lake’s vaccine candidate against respiratory syncytial virus (RSV), and Phase 1 clinical data on CVXGA, the companies’ vaccine candidate against COVID-19. Additionally, preclinical findings for a Lyme disease vaccine were presented.

BLB201: Intranasal RSV Vaccine

The interim analysis of RSV-seropositive children participating in the Phase 1/2a study demonstrated the safety and immunogenicity of BLB201. The data showed RSV F-specific systemic and mucosal antibody responses, as well as cell-mediated immune responses in CD4+ and CD8+ T cells.

CVXGA: Intranasal COVID-19 Vaccine

Phase 1 clinical trial data for CVXGA revealed COVID S-specific systemic and mucosal antibody responses and T cell-mediated responses, suggesting the potential of the intranasal vaccine to elicit a broad immune response.

Lyme Disease Vaccine

CyanVac scientist Cristina Gingerich, PhD, presented preclinical data on a parainfluenza virus 5 (PIV5)-based vaccine for Lyme disease. The study, a collaboration with Immuno Technologies, Inc., demonstrated that the intranasal vaccine induced protection against multi-strain Borrelia burgdorferi tick challenge in mice. The project was supported by the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

Intranasal Vaccine Approach

"Our vaccine approach is designed to stimulate potent immune responses from the humoral, cellular, and mucosal pillars of the immune system," said Biao He, Ph.D., CEO of Blue Lake and CyanVac. He added that current vaccine technologies like mRNA and protein-based vaccines are often administered intramuscularly and are not as effective in inducing mucosal immunity. The intranasal vaccine approach aims to prevent disease transmission and generate longer-lasting immunity by stimulating all three pillars of immunity.